These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32088875)

  • 1. In Vivo Administration of Splice Switching PNAs Using the mdx Mouse as a Model System.
    Brolin C; Lim EWK; Nielsen PE
    Methods Mol Biol; 2020; 2105():241-250. PubMed ID: 32088875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H; Lu Q; Wood M
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
    Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
    Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model.
    Brolin C; Lim EWK; Grizot S; Olsen CH; Yavari N; Krag TO; Nielsen PE
    Nucleic Acid Ther; 2021 Jun; 31(3):208-219. PubMed ID: 32678992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
    Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
    Williams JH; Sirsi SR; Latta DR; Lutz GJ
    Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M; Spitali P; Datson N; Aartsma-Rus A
    Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
    Lu-Nguyen N; Dickson G; Malerba A
    Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.